Advancing Treg-Modulating Therapies in Dermatological Conditions Through Clinical Validation
2:30 pm - Wednesday 24th March 2027
- Evaluating clinical trial strategies for Treg-directed and Treg-modulating therapies in dermatological autoimmune diseases to demonstrate meaningful patient benefit
- Leveraging accessible tissue biopsies to generate mechanistic insights and support pharmacodynamic biomarker development for clinical decision-making
- Defining clinical differentiation through durability, biomarker assessment, and patient selection strategies to strengthen the path toward broader adoption and partnership interest